Drug intelligence / Profile preview

TI-076

Development stage
Preclinical
Lead developer
Thera-I
Administration
Oral
01

Overview

TI-076 is a standardized aqueous extract of *Ilex paraguariensis* (Yerba Mate) being developed as a phytomedicine for the treatment of obesity and associated metabolic disorders, including diabetes, hypertension, and metabolic dysfunction-associated steatohepatitis (MASH). Preclinical studies indicate that TI-076 reduces body weight, hyperglycemia, and liver fat accumulation while improving lipid profiles and reducing inflammation. Its mechanism of action involves the modulation of genes related to inflammation (e.g., IL-1β, NLRP3), lipid metabolism (e.g., PPARα, PPARγ), and fibrosis (e.g., COL1A1). Additionally, it has been shown to increase levels of glucagon-like peptide-1 (GLP-1) and reduce food intake. The extract is designed to be a safe, scalable, and stable therapeutic option for multifactorial metabolic diseases.

Other names
Ilex paraguariensis extractYerba mate extract
02

Targets

GLP1R (GLP-1R)PPARA (Peroxisome proliferator-activated receptor alpha)CCKAR (Cholecystokinin A receptor)PPARG (Peroxisome proliferator-activated receptor gamma)FAAHIL1B (Interleukin-1 beta)MGLL (Monoacylglycerol lipase)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on TI-076.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TI-076.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call